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Influenza is a major challenge to healthcare systems world-wide. While prophylactic vaccination is largely
efficient, long-lasting immunity has not been achieved in immunized populations, at least in part due to the
challenges arising from the antigen variation between strains of influenza A virus as a consequence of genetic
drift and shift. From progress in our understanding of the immune system, the mode-of-action of vaccines can
be divided into the stimulation of the adaptive system through inclusion of appropriate vaccine antigens and of
the innate immune system by the addition of adjuvant to the vaccine formulation. A shared property of many
vaccine adjuvants is found in their nature of water-insoluble precipitates, for instance the particulate material
made from aluminum salts. Previously, it was thought that embedding of vaccine antigens in these materials
provided a “depot” of antigens enabling a long exposure of the immune system to the antigen. However, more
recent work points to a role of particulate adjuvants in stimulating cellular parts of the innate immune system.
Here, we briefly outline the infectious medicine and immune biology of influenza virus infection and procedures
to provide sufficient and stably available amounts of vaccine antigen. This is followed by presentation of the
many roles of adjuvants, which involve humoral factors of innate immunity, notably complement. In a
perspective of the ultrastructural properties of these humoral factors, it becomes possible to rationalize why
these insoluble precipitates or emulsions are such a provocation of the immune system. We propose that the
biophysics of particulate material may hold opportunities that could aid the development of more efficient
influenza vaccines.
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Seasonal influenza is one of the most common infections
in humans. In general, symptoms are mild. However,
elderly people and patients with a compromised immune
response, or an otherwise impaired health may ultimately
succumb to severe complications of the infection. For
this reason, there is an important and continuous need
for vaccine development, and production. Influenza
vaccines only provide strain specific protection. Because
of antigenic drift, vaccines are tailored to the present* Correspondence: vorup-jensen@microbiology.au.dk
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reproduction in any medium, provided the orcirculating strains each year. A change of vaccines is
also needed when antigenic shift occurs, and a new
pandemic arise. With the challenges in production and
distribution in mind, a pan-protective influenza vaccine
providing long-term protection would be a huge step
forward.
In this paper, we argue that one strategy to achieve this
goal is through the use of better adjuvants, in particular
these inducing an immune response mimicking the
natural infection.
Several decades of research have unravelled the mech-
anisms of the immune system, which are important in
protecting against influenza virus infection. It is now
clear these mechanisms prominently involve contributions
from both the innate and adaptive immune system. InLtd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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erable uniformity in the choice of antigenic components
in influenza vaccines, and hence how to guide the adaptive
immune response in fighting the virus. Some vaccines
include adjuvants, which largely act by stimulating the
innate immune system, thereby priming a stronger response
by the adaptive immune system. Interestingly, the choices of
adjuvants are chemically diverse, but often with a particulate
nature, prompting C.A. Janeway (1943–2003) famously
to refer to these as “messy precipitates” [1].
Here, we discuss current trends in the development of
adjuvants for use with influenza vaccines. In “Introduction”
section, a brief outline is presented on the clinical man-
ifestations and viral biology of influenza virus together
with mechanisms of the immune system limiting the
infection. In “Adaptive immunity and formulation of
antigenic components in influenza vaccines” section,
some of the vaccine antigens used, and their route of
administration are compared. Finally, “Innate immunity
and immunogenic and physicochemical properties of
adjuvants” section reviews the pharmacological mode-
of-action of clinicallyused, and experimental adjuvants
in influenza vaccines by elaborating on the potential for
adjuvant particle-size-related immunomodulatory stimuli.
Clinical manifestations of influenza virus infections
Droplet transmission and physical contact with virus-
contaminated surfaces seems to be the primary means
of influenza virus dissemination prior to inoculation
[2]. The incubation time is approximately 1 to 3 days
[3]. Cardinal manifestations of disease are malaise and
headache during the prodromal period. This is followed
by a sore throat, due to laryngotracheobronchitis and
hyperaemic, or erythematous oral and pharyngeal mucous
membranes associated with catarrhalia, rapid increase
in body temperature, non-productive cough, dedolation,
chills, and myalgia. The severity of the symptoms depends
on the degree of immunity raised by past infections.
Pre-existing conditions disposing a more severe disease
include pregnancy where seasonal influenza provokes a
3–4 fold increased risk of cardiopulmonary illness, notably
in the third trimester [4]. Chronic lung diseases or affected
respiratory function due to respiratory muscle atrophy,
cardiovascular diseases, diabetes, chronic liver and kidney
diseases [5], acquired immunodeficiency [6], or obesity [7]
also predispose to an aggravated course of the infection.
Children infected with influenza usually present the
same symptomatology as in adults, however, frequently
with higher body core temperature, croup, otitis media,
bronchiolitis, abdominal pain, and vomiting. Furthermore,
unlike in adults, influenza-associated mortality in children
appears not to be associated with an underlying medical
condition [8]. Persistent fever, i.e., for longer than five
days, may be a consequence of bacterial co-infections withStreptococcus pneumonia, Haemophilus influenza and
Staphylococcus aureus. These pathogens cause sinuitis,
otitis, bronchitis and/or pneumonitis. Co-infections with
Staphylococci are fulminant and even lethal [9,10]. In
more general, the bacterial pathogens may cause septic
shock as well as exacerbate pulmonary and cardiac
diseases [11-13].Architecture and strain diversity of the influenza virus
Influenza viruses are the only members of the Orthomy
xoviridae family. They are classified into three different gen-
era, A, B and C, based on the expression of matrix (M1)
protein, membrane (M2) protein and nucleoprotein (NP).
Orthomyxoviridae viruses have several biological properties
in common. However, they differ significantly in their host
tropism [14]. Influenza viruses of genera B and C princi-
pally infect humans, although they occasionally have been
isolated from seals and pigs [15,16]. Influenza A viruses, on
the other hand, propagate in several animal hosts, including
humans, pigs, horses, minks, and in domestic and wild
birds. Waterfowls are the primary reservoirs, in which the
virus is hosted in the intestine. Several species act as mixing
vessel between humans and birds, primarily the pig, which
express receptors for both human and avian viruses in
their upper respiratory tract epithelial cells. In general,
influenza A viruses are nonpathogenic in birds and are
classified as either low or high pathogenic avian influenza
viruses (LPAI or HPAI, respectively), depending on the
morbidity and mortality upon transmission to other
species, including humans [17].
Subtyping of influenza viruses is based on the antigenic
properties of their surface hemagglutinin (HA) and neur-
aminidase (NA) glycoproteins. Currently, 17 different
subtypes of HA have been identified, of which the
most recent (H17) was identified in fruit bats [18]. Nine
different subtypes of NA are known. The influenza virion
(Figure 1) contains a linear, negative sense, single-stranded
RNA with 7 (C genus) or 8 (A and B genera) segments,
each expressing one or two of the influenza virus proteins.
The segmented genome of the influenza virus facilitates
genomic changes by genetic drift and/or genetic shift.
Genetic drift refers to minor changes due to mutation in
the genes encoding HA or NA, altering viral antigenicity.
Such alterations are sufficient to permit infections in indi-
viduals with immunity to similar viruses, and drift explains
the regular outbreaks of seasonal influenza. Genetic shifts
are major changes as a result of reassortment of genome
segments from different human and/or animal strains
producing anything from slightly to completely different
influenza virus genomes. In this situation little pre-existing
immunity to the virus can be found in human populations,
potentially leading to severe pandemics. The latter process
is restricted to virus of the A genus [14].
Figure 1 Architecture of the influenza virion. While the virus has often been depicted as spherical in microbiology textbooks [14], recent
investigations suggest a far more pleiomorph appearance, only some particles being essentially spherical while others are tubular. The approximate
length of the virion is 120 nm, possibly influenced by the organization of the RNA by the multiple ribonucleoprotein complexes [19] shown in the
center of virion surrounded by the capsid and layer of matrix protein M1. The relative abundance of the HA and NA proteins are indicated based on
reports by Mitnaul et al. [20] and Zhang et al. [21] (components not to scale). Based on data from the report by Gjelstrup et al. [22], a 6×MBL3 oligomer
is drawn to scale relative to the size of the influenza virion.
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The requirements for influenza A virus infectivity are well
studied. These viruses depend on sialic acid expression
on the host tissue, which permits the attachment of the
viral HA proteins. Human influenza virus mainly infects
non-ciliated cells in the respiratory tract, while the
avian virus infects ciliated cells [23], thereby reflecting
the carbohydrate selectivity of HA. The avian viruses
prefer attachment to galactose residues forming an α-
(2,3)-glycosidic linkage to the sialic acid, while human
viruses preferentially bind to galactose residues forming
an α-(2,6)-linkage [24]. Pigs have both types of sialylations
in their upper respiratory tract, while humans express
α-(2,6)-galactose linked sialic acid in the upper respiratory
tract and α(2,3)-galactose linked sialic acid in the lower
respiratory tract [25]. NA activity is essential both to
ensure the release of virus from infected cells, and to
facilitate the development of the infection by providing
access to the deeper layers of tissue, i.e. below the
sialylated lung mucus [26].
Following infection with the influenza virus, inflamma-
tory cells of the innate immune system accumulate in
the mucosal membrane. The cellular response to infection
involves hyperemia of the epithelium and necrosis in
bronchiolar epithelial cells [27]. At least in part, this
response is a consequence of the recruitment of neu-
trophil granulocytes to the site of inflammation andviral activation of epithelial cells [28]. The recruitment
of granulocytes depends on the proteolytic cleavage of
humoral factors of the innate immune system, particularly
the group of plasma proteins constituting the complement
system. Small fragments of these proteins, notably C5a,
permeate the endothelium of adjoining blood vessels in
the zone of inflammation and create a chemokine gradient
guiding the granulocytes [29]. It is a classic finding that
mannan-binding lectin (MBL, also known as mannose-
binding lectin or mannan or mannose-binding protein,
MBP), a complement-activating plasma protein, is signifi-
cant in the protection against influenza infection in ferrets
[30,31]. Evidence also suggests that MBL plays a similar
role in infections in humans [32]. MBL recognizes a
particular topological pattern of glycans on HA, thereby
triggering complement activation through the lectin
pathway [31,33,34]. Opsonization through the deposition
of proteolytic fragments of complement component C3
allows neutrophil granulocytes and other myeloid cells
to the viral particles through complement receptor
(CR)3 (also known as integrin αMβ2, Mac-1, or CD11b/
CD18) and CR4 (also known as integrin αXβ2, p150,95
or CD11c/CD18) [35]. Other pattern recognition mole-
cules, such as Toll-like receptors (TLRs), recognize the
single-stranded RNA transported into infected cells by
the influenza virus [36], which alerts cellular parts of
the immune system.
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virus, the innate immune system is also important in
priming a response by mechanisms of adaptive immun-
ity. Dendritic cells (DC) transport viral antigens into
the lymph nodes, where naïve T cells are converted into
influenza antigen-reactive CD8+ cytotoxic T lymphocytes
(CTL) or CD4+ T helper (Th) cells. T cell responses are
critical for protection against influenza infection, as
was established in a classic study on human volunteers
infected with an unattenuated strain of influenza virus
[37]. Perhaps surprisingly, a recent analysis showed that
CD4+ T cells with an interferon-γ-producing Th1 pheno-
type, and only to a lesser extent CTLs, are particularly
important in protection in humans [38]. Influenza vaccines
are evaluated by their ability to react with antibodies
[39]. While there is evidence that antibody titers to vaccine
antigens correlate with vaccine efficacy [39], the recent
identification of CD4+ Th1 cells as important in protection
against influenza infection [38] could raise a question if
antibody titers are a sufficiently comprehensive measure of
vaccine-induced immunity to infection. At the very least,
vaccine strategies permitting formation of such influenza
virus antigen-reactive T cells should be carefully considered
as discussed in “Adaptive immunity and formulation of
antigenic components in influenza vaccines” section.
Mature naïve T cells are maturated inside the thymus.
Thymic function declines, however, with age, due to a
gradual replacement of thymopoietic tissue with adipose
tissue [40-42]. Thus, it is not surprising that impaired
formation of antigen-specific antibodies in the elderly
was reported for influenza vaccination [42,43]. Although
the total size of the peripheral lymphocyte pool is stable
throughout life, the composition of both CD4+ and CD8+
T cells with regard to naïve and memory subpopulations
changes with age [42,44]. A modest decline of naïve CD4+
lymphocytes is observed until the ages of 65–75, due to
homeostatic control mechanisms, but subsequently the
naïve CD4+ T cell reserve collapses [42,45]. Consistent
with this, changes within the CD4+ naïve and memory
subsets have been shown to impair long-term CD4+ T
cell responses to influenza and hepatitis B vaccination
[42,46,47]. These observations are particularly important
in view of the essential role of these cells in protecting
against the infection [38,42].
At the molecular level one of the most profound bio-
logical indicators of ageing in the human immune system
is the progressive loss of expression of the co-stimulatory
molecule CD28 on T cells that have undergone repeated
antigen stimulations [42,48-50]. However, other mecha-
nisms may be affected as well. In vaccinees younger than
35 years, expression of the adhesion molecule CD62L was
observed to correlate with the ability to raise immunity to
the hepatitis B virus following vaccination with hepatitis
B surface antigen. The association between expressionof the adhesion molecule CD62L (L-selectin) on CD4+
naïve and central memory T cells and the formation of
antigen-specific antibodies was not found for donors
older than 55 years [47]. Age-related alterations in the
vaccine responsiveness may consequently affect vaccinees
far younger than previously thought [42,47]. Since the
function of CD62L pertains to general functions of T cells,
it is possible that the observations by Rosenberg et al.
[42,47] pertain to a wider number of vaccinations than
those protecting against hepatitis B virus, and this also
includes influenza vaccinations.
Adaptive immunity and formulation of antigenic
components in influenza vaccines
Advancements in understanding the etiology of infectious
diseases and especially how antigen responses are formed
through the adaptive immune system have provided
means for novel ways of vaccine production and adminis-
tration into the human body. The success of these accom-
plishments includes elimination of small pox as a human
infection and efficient vaccines against other viruses pro-
viding life-long protection. Indeed, the concept of vaccin-
ation is no longer limited to prevention of infectious
diseases, but is also used in modulating immune responses
in autoimmune diseases [51]. With the live-attenuated
small pox vaccine as an important example, vaccines
broadly stimulating the immune system in a manner re-
sembling the natural infection are far superior to most
sub-component based, or otherwise engineered vaccines.
By contrast, the prophylactic influenza vaccination has not
achieved to induce long-lasting immunity in immunized
populations [52]. To overcome this problem, the strategy
has focused on challenging the adaptive immune response
with influenza virus antigens tailored to the predicted up-
coming seasonal or pandemic influenza virus, although
the need for adequate supplies of vaccines and frequent
vaccination hinder efforts to obtain sufficient protection.
As an indication of load of vaccines supplied for single
season, the United States of America federal Food and
Drug Administration-recommended influenza vaccina-
tions for the season 2013–2014 are listed in Table 1. It is
tempting to suggest that inability to achieve long-lasting
protection is in consequence of the wide use of inactivated
or sub-component based formulations. However, the live-
attenuated influenza vaccine FluMist (Table 1) also re-
quires annual administration, suggesting that the biology
of the virus is the real culprit in limiting vaccine efficiency.
Below, we list major strategies for producing the antigenic
component of influenza viruses.
Protein-based vaccines against influenza
Influenza vaccine antigens are commonly formulated either
as whole inactivated virus or in vitro-expressed viral protein
subcomponents [53].
Table 1 Influenza virus vaccines for the United States of America 2013–2014 seasona
Seasonal influenza vaccines Type/abbrev. # Antigens Route of administration Manufacturer Age range Adjuvant
Afluria Inactivated/IIV3b Trivalent Intramuscular CSL Limited 5 ≥ None
FluLaval Inactivated/IIV3b Trivalent Intramuscular GlaxoSmithKline 18 ≥ None
Fluarix Inactivated/IIV3b Trivalent Intramuscular GlaxoSmithKline 3 ≥ None
Inactivated/IIV4b Quadrivalent Intramuscular None
Flublok Recombinant/RIV3c Trivalent Intramuscular Protein Sciences 18-49 None
Flucelvax Cell Culture/ccIIV3b Trivalent Intramuscular Novartis 18 ≥ None
FluMist Live Attenuated/LAIV4d Quadrivalent Intranasal Medimmune 2-49 None
Fluvirin Inactivated Trivalent Intramuscular Novartis 4 ≥ None
Fluzone Inactivated/IIV3b Trivalent Intramuscular Sanofi Pasteur 6 mo ≥e None
Inactivated/IIV4b Quadrivalent Intramuscular None
aU.S. Food and Drug Administration recommends that the trivalent-formulation influenza vaccines for the U.S. 2013–2014 influenza season contain the following:
(1) A/California/7/2009 (H1N1)-like virus, (2) (H3N2) virus antigenically like the cell-propagated prototype virus A/Victoria/361/2011, and (3) B/Massachusetts/2/
2012-like virus. For the quadrivalent-formulation influenza vaccines for the U.S. 2013–2014 influenza season contain the above three strains and the following
additional B strain: (4) B/Brisbane/60/2008-like virus. bIIV refers to inactivated vaccines (egg and cell-culture based). Includes trivalent (IIV3) and quadrivalent (IIV4).
cRIV refers to recombinant HA influenza vaccine. Trivalent (RIV3). dLAIV refers to Live Attenuated Influenza Vaccine. Quadrivalent (LAIV4). eDose dependent.
Informations were found on web sites: http://www.emergency.cdc.gov/coca/ppt/2013/08_13_13_Immunizations.pdf, http://www.fda.gov/biologicsbloodvaccines/
guidancecomplianceregulatoryinformation/post-marketactivities/lotreleases/ucm343828.htm (accessed on 4 September 2013).
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most widely used, covering approximately 90% of human
vaccine sales world-wide [54]. A new avian influenza
vaccine is normally made by inoculation of the isolated
virus into embryonated chicken eggs. The manufacturing
process has been described in detail elsewhere [54].
Briefly, the allantoic fluids from influenza virus-inoculated
embryonated eggs are collected in a fully automated
process followed by a simple clarification step. The virus is
recovered through multiple filtration and concentration
steps and inactivated with chemicals such as formalin
or β-propiolactone, typically in two steps [54]. The final
influenza vaccine is trivalent with two strains of Influenza
A virus (H3N2 and H1N1) and one strain of Influenza B
virus to provide a suitable antigenic range that will meet
the viral challenge of the season [55]. However, several
problems in such manufacture remain poorly resolved.
First, a stable supply of eggs is needed, which has required
drastic reorganization of hen flock management [54].
Second, the egg-based viral culture is not efficient in
producing high titers of virus with antigenic and gen-
etic fidelity. Hence, there is a question of whether this
procedure permits production on a scale that would
be able to protect against a serious pandemic. Third,
the potential susceptibility of chickens to HPAI viruses
further jeopardizes the availability of eggs for vaccine
production in the event of a pandemic strain arising
from an HPAI virus [56].
A simpler approach to make influenza antigens in cell
cultures routinely involves the synthesis of protein sub-
components of the virus using recombinant methodologies
[57]. Several experimental enquiries are further exploring
these possibilities by testing multiple host cell types for
efficacy in producing different recombinant influenzaantigens. HA was made in insect cells [58], the M2 protein
in plant cells [59] as well as Escherichia coli, where this
protein was conjugated to the TLR-5 ligand flagellin [60],
or the heat shock protein (HSP)-70 of Mycobacterium
tuberculosis [61]. As discussed further in “Innate immunity
and immunogenic and physicochemical properties of
adjuvants” section, these adjuvants are necessary since the
subunit antigens are generally poorly immunogenic.
In vivo-expressed influenza DNA vaccines
DNA vaccines are basically expression constructs that
will produce the encoded antigen following delivery of the
construct to an appropriate host cell. Compared with
the production of whole viruses or viral subcomponents,
DNA vaccines are easy to manufacture and extraordinarily
stable when stored in the lyophilized state.
DNA vaccines have been applied as model systems to
study the possibility of inducing antibodies against the
HA, NP, and M1 proteins [62,63], the ability to raise
CTL response, and to investigate the protection in mice,
chicken, ferrets and primates using intranasal instillation,
intravenous injection, intramuscular injection, or gene gun
[62,64]. These experiments confirmed that influenza DNA
vaccines can induce humoral and cellular responses, and
the animal will get full or partial immunity to the chal-
lenge [62]. In mice, the antibody formation against HA
was mostly of IgG2a isotype, but switched to IgG1 when
the gene gun was used. IgG and IgA antibodies to HA
were also secreted to the upper respiratory tract of vac-
cinated animals [65]. In primates, the titer was as high
as the titer induced by human commercial influenza
vaccines [66]. In mice, NP-coding DNA vaccines were able
to increase the level of CD8+ CTL as well as the cellular
immune response, which can give proper immunity to a
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vaccination with the influenza DNA vaccine coding NP
helped to induce high levels of secretion of CD4+ Th1,
and to increase the levels of interferon-γ and interleukin-
20 [67]. Both CD8+ CTL and CD4+ T-cells gave protec-
tion against influenza challenge [65]. In view of the recent
findings that interferon-γ-secreting CD4+ Th cells are
important in obtaining protection against influenza virus
infection [38], DNA vaccination may carry particularly
beneficial properties in shaping the right phenotypic
composition of influenza virus antigen-reactive T lympho-
cytes. However, in spite of nearly two decades of research,
influenza DNA vaccination in clinical trials has not been
an unqualified success, suggesting that both choices of
antigens and adjuvants as well as the means of DNA cell
delivery may need reconsideration [55].
The Flumist vaccine (Table 1) with live-attenuated virus
represents an important alternative to obtain in vivo
expression of influenza virus antigens, this way supporting
T cellular responses. In this case, an attenuated master
donor virus with appropriate characteristics with regard to
cold-adaptation and stability is mixed in cell cultures with
a potentially epidemic wild-type virus. This procedure
reassorts the RNA segments of the master donor such that
it will encode the HA and NA of the wild-type virus [68].
Innate immunity and immunogenic and
physicochemical properties of adjuvants
Vaccines are occasionally formulated with adjuvants to
augment the potency of the antigen and presentation to
the immune system. These co-administered adjuvants may
enhance humoral and cellular immune responses simul-
taneously [69]. Adjuvants comprise a surprisingly diverse
range of compounds, including mineral salts, oil-in-water
emulsions, saponin-based adjuvants, liposomes, micropar-
ticles, cytokines, and polysaccharides [70]. Pandemic influ-
enza vaccines are formulated with adjuvant since they
are typically monovalent and meant to protect immuno-
logically naïve vaccinees. Among seasonal influenza
vaccination, as noted from Table 1, none of the 2013–
2014 seasonal vaccinations contains adjuvants. Never-
theless, as presented further below, several experimental
approaches clearly support that improvement of adjuvant
efficacy may be an important route to obtaining better
protecting influenza vaccines or reduce the dosage needed
to obtain sufficient protection.
Historically, vaccine adjuvants were developed empir-
ically, initially based on an assumption that the antigen
adsorption onto solids would prolong the stimulus in vivo
[71,72]. In a broad outline, their immunostimulating
contributions are currently considered as relating to (1)
chemical stabilization of vaccine antigens, (2) improving
antigen delivery to antigen-presenting cells, (3) improving
antigen processing and presentation by antigen-presentingcells, (4) stimulating the production of desirable immuno-
modulatory cytokines, and (5) permitting a decrease in the
required dosage of the administered antigen. It is clear
that the innate immune system is involved in all of these
effects. In an important treatise defining the concept of
innate immunity, Janeway noted that immune responses
raised to soluble proteins in experimental models almost
always required the further addition of “messy precipitates”
[1], which apparently deliver a stimulus required for effi-
cient formation of antigen-specific immunity. As noted in
“Protein-based vaccines against influenza” section, indeed
adjuvants are obligatory in vaccines based on viral subcom-
ponents such as the pandemic influenza vaccines. Janeway
concluded that this stimulus was triggered by “nonclonal
recognition of nonself patterns” [1]. This is now widely
recognized in the concept of adjuvants mimicking patho-
gen-associated molecular patterns [73,74], and supported
by observations on pattern-recognition receptor agonists
used as adjuvants [75]. However, the particulate nature of
many adjuvants has received less attention as part of the
explanation for the mechanisms of adjuvants. As explored
further below, the particulate nature of many adjuvants
may add an ultrastructural feature to the vaccine formula-
tion, which is likely to activate both humoral and cellular
factors of the innate immune system.Licensed adjuvants in clinical use
Among adjuvants that have obtained a license in the
European Union (Table 2), aluminum salts, oil-in-water
emulsions (e.g., MF59), alum-adsorbed TLR4 agonists (e.g.,
adjuvant system [AS] 04), and liposomes (e.g., Crucell), are
the most widely used [80]. The list of licensed adjuvants in
the United States is even more restricted, and includes
only aluminum salts and AS04 [81] (Table 2).
Aluminum salts are widely used as adjuvants and are
included in the hepatitis B virus, papillomavirus, and
diphtheria-tetanus-pertussis vaccines [72]. The majority
of aluminum salt adjuvants used in humans comprise
amorphous aluminum hydroxyphosphate (Al(OH)x (PO4)y),
amorphous aluminum hydroxysulfate (generated from
precipitation of the antigen with AlK(SO4)2 named alum),
and aluminum hydroxide, which is more correctly described
as aluminum oxyhydroxide, AlO(OH) [76]. These salts
are insoluble in water and form particles disperse in
size (Table 2).
Studies have demonstrated the apparent superiority of
aluminum hydroxide-adsorbed vaccines when compared
to soluble adjuvants [82]. However, aluminum salts are
ineffective in providing immunity against pathogens
requiring Th1 mediated immunity [83,84]. Their mode-of-
action were previously considered to support antigen
persistence in vivo by prolonging antigen release. This
effect is often referred to as the “depot effect”, although
Table 2 Approximate diameters and chemical constituents of particulate adjuvants used in humans for prophylactic











Mineral salts Aluminium hydroxyphosphate or Aluminum
hydroxysulfate or Aluminum oxyhydroxide
Various
MF59 (Novartis; 1997) 160c Oil-in-water
emulsion
Squalene, polysorbate 80, sorbitan trioleate Fluad (seasonal influenza), Focetria (pandemic


















Aluminum oxyhydroxide, MPL Fendrix (hepatitis B), Cervarix (human papilloma
virus)
aData reported are for the vaccine formulations with antigens. bValues are from a review by Hem & HogenEsch [76]. cValue from a review by O’Hagan et al. [77].
dValue from a review by Garcon et al. [78]. eValue from de Jonge et al. [79].
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[85]. The aluminum salt particles may rather serve to
activate macrophages and dendritic cells [72,86]. With
regard to safety, aluminum salts have been commercially
available for several decades [87], and are generally consid-
ered well-tolerated [88]. However, experimental evidence
suggests that complexing of Al3+ ions with glucose-6-
phosphate may interfere with the energy metabolism in
a way that at least on speculative grounds might link
high concentrations of aluminum to neural disorders or
inflammatory syndromes [89].
Oil-in-water emulsions based on the natural lipid prod-
uct squalene, i.e., MF59, are licensed in most parts of
Europe to be used with an updated seasonal influenza
vaccine, primarily in elderly vaccinees. Moreover, MF59 and
AS03 are the adjuvants of choice in pandemic influenza
vaccines [74,90]. Although made from a softer material
than the aluminum salts, the squalene and polysorbate
mixture nevertheless in aqueous environment manage to
form stable droplets as a consequence of the hydrophobic
effect [77,78] and a diameter of ~100 nm [91]. As is also
the case for mineral particles, the oil-in-water interface may
adsorb protein from the medium, such as albumin [92].
In terms of the pharmacological mode-of-action, MF59
presumably acts by inducing a local immunostimulatory
environment at the site of injection. This is characterized
by enhanced antigen persistence, an increased antigen
uptake by dendritic cells, and the recruitment of APCs
[90,93]. Oil-in-water emulsions induce stronger antibody
responses, which reduce the need for multiple doses, and
lead to a combined Th1 and Th2 memory response [94].
The administration of squalene has been associated with
the development of arthritis in rats [95]. Nevertheless,
the evidence so far presented does not suggest significant
or frequent side effects prompted by the use of squalene
adjuvant in humans [96]. The H1N1 influenza vaccinationPandemrix contains squalene. Application of the vaccin-
ation was suggested to be associated with the development
of narcolepsy in children [97,98], a disorder which involves
the immune system [99]. However, it is unclear what role,
if any, the AS03 adjuvant played in these clinical findings.
Other vaccines utilize a new class of adjuvant systems
(AS04), which combine aluminum hydroxide and a
proprietary form of detoxified monophosphoryl lipid A
(MPL). MPL is derived from the gram-negative bacterium
Salmonella minnesota R595 strain, and is a specific agon-
ist of TLR4, comparable to lipopolysaccharide [100-104].
Indeed, lipopolysaccharide may also potentiate the im-
mune response. However, frequent pyrogenic activities
preclude the use of lipopolyssacharide as adjuvant for
human use [72,74,83]. In contrast, the less toxic MPL is
administered in vaccines for human use without any
reported adverse effects [105]. AS04 directs a polarized
Th1-response, as opposed to the Th2 response of
aluminum salt alone. While the adjuvant activity of this
formulation can mostly be ascribed to MPL, the “depot
effect” of aluminum was suggested to prolong the
stimulation by MPL [74,83].
Similar to the more familiar liposomes, virosomes are
composed of a phospholipid bilayer, but unlike liposomes,
the bilayer is unilamellar and modified with viral envelope
proteins (e.g., in the case of influenza-like particles with
NA and HA anchored in their virosomal membrane).
In this way, virosomes are designed to bind and fuse
with host cells similar to their cognate viruses. Antigens
anchored to the surface are degraded upon endosomal
fusion within the endosome and are consequently dis-
played to the immune system by MHC class II receptors.
In contrast, antigens encapsulated within the virosomes
are transported to the cytosol during the fusion event,
which enables them to enter the MHC class I pathway of
antigen presentation. Hence, virosomes possess the
Jalilian et al. Molecular and Cellular Therapies 2013, 1:2 Page 8 of 16
http://www.molcelltherapies.com/content/1/2capability of mediating humoral as well as cell-mediated
immune responses [106,107]. Currently, two commercial
vaccines utilizing the virosome technology have acquired
a license: Epaxal® against hepatitis A and Inflexal® against
influenza. Both are proven to be effective immunogens
with unique adjuvant properties [108].
New generation of adjuvants for influenza vaccines
Novel vaccine adjuvants are designed to favour stronger
responses as well as the development of Th1, Th2, or
CTL-mediated immunity. Cationic liposomes are such
strong activators of the immune system. As already men-
tioned above, selective cellular responses may be required
to offer efficient immunity to influenza [109]. To achieve
this goal, genetic adjuvants and cytokines may be efficient.
In general, genetic adjuvants are constituted by plasmid
vectors encoding immunomodulatory products, such as
cytokines [110]. Interestingly, novel directions in the
design of genetic adjuvants include the use of DNA
motifs such as CpG or HSPs from Mycobacterium.
Cationic liposomes are potent stimulators of the im-
mune system [111,112]. While there is a considerable
literature on experimental use of such liposomes as
adjuvant, it is only recently that promising clinical trials
have been conducted [113]. At least two influenza vaccines
with cationic liposomes as adjuvants have been tested in
clinical trials [114,115]; one addressing the complications
mentioned in “Viral infectivity, treatment, and immunity
to influenza” section of raising protective immunity in
the elderly vaccinees [115]. The cationic adjuvant formula-
tion no. 1 (CAF01) consists of dimethyldioctadecylam-
monium and α,α‘-trehalose-6,6′-dibehenate (TDB) [116].
TDB is a synthetic analogue of trehalose 6,6′-dimycolate,
which itself possess an unwanted toxicity. However, by pre-
serving the Mycobacterium-like lipid structure in TDB, the
CAF01 formulation makes it possible to raise an immune
response to antigens from Mycobacterium, such as
the early-secreted antigenic target 6 kDa (ESAT-6). The
mode-of-action of the adjuvant seems to involve the
TLR-independent Syk/Card9-dependent pathway [116],
apparently through direct binding to the C-type lectin
receptor Mincle expressed in macrophages [117]. These
findings points to an interesting principle in the choice
of appropriate adjuvants also explored below, namely
efficient adjuvants as a source of an innate immune re-
sponse similar to those induced by the target microbial
organism. As a tool to direct T cellular response the
CAF01 cationic lipid composition appears to produce a
Th1 response [118], but examples of cationic lipids
stimulating Th2 response are also reported [118,119].
Unmethylated bacterial CpG motifs are commonly used
recombinant adjuvants that can induce innate immune
response to DNA vaccines. Because CpG motifs in ver-
tebrates are often methylated, bacterial CpG motifs arerecognized as pathogen-associated molecular patterns
by the human immune system, typically by TLR-9 after
receptor-mediated endocytosis [120-122]. CpG motifs
enhance both humoral and cellular immune responses to
the encoded vaccine antigen, skewing the cellular response
towards Th1 phenotype [123]. Recently, CpG DNA
formed an important part in DNA vaccine protection
against Mycobacterium tuberculosis, with ability of the
adjuvant to augment the lung infiltrate of interferon-γ
producing T lymphocytes [124]. This finding is not,
however, independent of the microbial challenge or
applied vaccine antigen. Wu et al. showed that addition
of CpG DNA may even weaken the protective activity
of the influenza M2 protein vaccine [125].
In three independent studies, Mycobacterium-dependent
protein-1, HSP 70, and ESAT-6, respectively, were used as
potential genetic adjuvants for the avian influenza H5
DNA vaccine [61,126,127]. HSPs are chaperones and play
an important role in protein folding and prevention of
protein aggregation or misfolding. Previous studies have
shown the high potential of HSPs as genetic adjuvants in
DNA-based vaccination, probably due to their capacity to
stabilize weak antigens, permitting the delivery to APCs,
notably DCs [128]. When fused to vaccine antigens,
HSPs or heat shock cognate proteins can elicit CD8+
CTL response in vivo and in vitro [129]. Optimal
results are obtained if they are directly fused with the
vaccine gene of interest [61,130,131]. Rasoli et al. tested
a potential enhancement of immunogenicity of an avian
influenza virus DNA vaccine, where the H5 gene was
fused with the HSP-70 gene [61].
Adjuvants as particulate material and immunogenicity
Many commonly applied adjuvants precipitate in aque-
ous environment and remain stable as particles once ad-
ministered suggesting this property to be important.
With doubts being cast on the “depot” effect as rationali-
zing the effect of adjuvant [85], it remains enigmatic pre-
cisely why “messy precipitates” as adjuvants are such a
provocation of the immune system. As detailed in an
excellent review by Fox et al. [132], the physicochemical
properties of particulate materials affect, however, many
aspects of vaccine efficacy. Indeed, as noted above, other
physicochemical properties such as surface charge of the
particulate material has received interest, while the size
of these particles are not often mentioned even though it
is an intrinsic property of precipitates.
We propose that the colloidal nature of several adjuvants
(Table 2) influence the immune system through three
highly interconnected routes.
First, the deposition of soluble proteins of the innate
immune system on particle surfaces stimulates in many
cases a proinflammatory response. Notably, these proteins
include components of the complement system, which
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innate immune system. In this situation, peptides released
by the complement activation make the adjuvants proin-
flammatory “by-standers”, which influence the vaccine
response indirectly by activating leukocytes. Second, both
the deposition of complement as well as a spontaneous
deposition of other proteins on the adjuvant particle
surface, such as the abundant plasma proteins fibrinogen
or albumin may generate cues for recognition by receptors
expressed on leukocytes. This is a less indirect route of
stimulating leukocytes to vaccine antigen responses since
such protein-coated adjuvants directly interact with the
leukocytes involved in the process. Third, the biophysical
characteristics of particulate material, e.g., size and surface
charge, may dramatically influence cellular uptake and re-
sponse [133]. This phenomenon relates to both the rigidity
of the cell membrane, and the accompanying molecular
interactions permitting receptor recognition of ligands on
the particulate surfaces Figure 2. As reviewed below, hereFigure 2 The sources and consequences of plasma protein deposition
well-described for liposomes and is likely to happen on the surface lipid ad
oxide particles is less characterized [148]. As clear from the schematic, a pa
topological restraints, which may influence both the complement activatio
elsewhere [134]. Following activation of the complement components C3,
concomitantly with the proteolytic release of small peptides from the mole
complement activation and may hence create a signature for adjuvants. In
the adjuvants act as by-standers creating a milieu of immunostimulatory p
fragments, which is ligand for both CR3 and CR4 and may thus support ph
of these receptors with cytoskeleton. In addition to complement, surface-a
because of the structural denaturation of the protein as a consequence of
receptors [155,156]. Sizes are indicated approximately to scale based on dait appears that size per se is an important factor in the
direct interactions between the adjuvant and leukocytes.
The complement system is constituted by approximately
40 soluble plasma proteins and receptors. In essence,
the function of complement involves the capability of
the soluble proteins to transform into a surface-bound
state with deposition on target surfaces, e.g.; the cell walls
of bacterial or fungal organisms, envelopes or capsids of
viruses, or even decayed host tissue or apoptotic cells. The
pathways of activation have been detailed elsewhere [134].
Briefly, three distinct mechanisms initiate the deposition
of complement. The classical pathway (i) is activated by
binding of the complement component (C) C1 complex to
IgG or IgM antibodies. Followed by proteolytic activation
of C4 and C2, which generate the surface-bound frag-
ments C4b and C2a and the small soluble fragments C4a
and C2b, an enzyme C4bC2a is formed, which converts
C3 into surface-bound C3b and the soluble fragment C3a.
A similar process, named the lectin pathway (ii), may beon particulate adjuvants. Deposition of complement is
juvants as well [142]. The deposition of complement on aluminum
rticle with a diameter of ~100 nm presents certain space and
n and actually capacity for carrying deposited protein as detailed
C4, and C5 these are covalently bound to target surfaces
cules (indicated with colors). This release depends on the pathway of
this scenario, which does not explicitely involve the vaccine antigen,
eptides. Proteolytic processing of the C3b fragment creates the iC3b
agocytosis by “professional phagocytes” [161] through the connection
dsorbed fibrinogen is a ligand for CR3 and CR4, probably in part
the surface adsorption, which enhances the interaction with these
ta presented in Refs. [134,166,167].
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by binding of ficolins to certain acetylated compounds
[135]. Finally, the alternative pathway (iii) is based on
the ability of C3 to deposit spontaneously on nearly all
biological surfaces. Host cells may catalyze the removal
of C3 and other complement components from their
cell surface. By contrast, many microbial cells do not
harbour such mechanisms, and are hence susceptible to
complement attack. Following the covalent deposition
of C3b, a complex with the proteolytic part of activated
Factor B (termed Bb) is formed. Unlike C4bC2a enzyme,
the C3bBb enzyme permits a positive amplification loop
since the deposition of more C3b creates more enzymes.
Further proteolytic degradation in situ generates the iC3b
and C3d fragments, which are ligand for complement
receptors (CR)2 and CR3. Also, the C4bC2a and C3bBb
enzymes enables the recruitment of the large C5b to
the surface, while releasing the small C5a peptide to the
environment. C5a is a strong activator of the endothelium
of blood vessels, and central in the recruitment of many
inflammatory cells to the site of complement activation.
Complement has long been known to play a quintes-
sential role of in raising a strong antibody response to
antigens [136], now more fully understood with the help of
intravital fluorescent microscopy of the cellular processes
involved in the lymph node [137,138]. A part of the benefit
from complement activation may derive from the covalent
coupling of a proteolytic fragment of C3 (C3d) to antigens,
this way supporting the uptake by B cells through CR2.
This has already been explored as a so-called “molecular
adjuvant” in experimental studies by engineered coupling
of this fragment onto target antigens, including influenza
vaccine antigens [139-141].
A less appreciated route of complement influencing
the function of adjuvants involves direct activation of
complement. Indeed, it is well established that lipid vesicles
in the kind of liposomes may activate the complement sys-
tem [142,143]. The in vivo significance of this phenomenon
is well-known in the field of drug delivery. Such activation
accelerates the clearance of the liposome from free circula-
tion through capture by hepatic macrophages in a process,
which is very similar to the fate of viral particles opsonised
by complement. More recently, it has become clear that
poloxamers, a type of pluronic block co-polymers, also
activate the complement system as well as more widely
affects cellular functions when administered [144,145].
Poloxamers have been tested in the context of experimental
DNA vaccines to influenza virus [146]. The benefit from
this addition was probably in part obtained by improving
DNA drug delivery [146]. Nevertheless, it is tempting to
suggest that complement activation by poloxamers also
contributed to the immunogenicity due to the complement
system’s many influences on the inflammatory response.
Interestingly, these poloxamers as well as drug deliveryliposomes and lipidic adjuvants used in the clinic (Table 2)
attain diameters of 100–200 nm [77-79,146], similar to
the dimensions of influenza virus particles with a diameter
of ~120 nm (Figure 1) [19]. This is a conspicuous property
of both the adjuvant and viral particles since Pedersen et al.
[147] reported that nanoparticles with structural features
similar to molecular initiators of complement activation
produced stronger responses than particles with either
smaller or larger sizes than these initiators. At least in
serum from some donors the strongest activation was
clearly found for dextran-coated polystyrene or iron oxide
particles with diameters of 100–250 nm, apparently pend-
ing a sufficient titer of anti-dextran IgM. This effect was
attributed to perturbations in the ultrastructure of IgM
with cross-sectional diameters in the order of 20–30 nm
[134], when IgM bound epitopes on the curved surface of
the particles. With regard to aluminium salts and phos-
phate adjuvants, these are composed of small (~50 nm)
primary particles, similar in size to the lipid adjuvants.
The antigen-precipitated particles are, however, far larger
than those generated from lipid adjuvants, typically with
diameters ~1,000-20,000 nm [76]. This would seem to
preclude complement activation through the processes
addressed by Pedersen et al. [147]. Furthermore, while
aluminium salt particles activate complement [148], there
is evidence that at least hydrated aluminium surfaces
adsorbed complement in a manner not generating the
typical proteolytic cleavage products associated with acti-
vation [149]. This could point to significant differences
between particulate adjuvants in their interaction with the
complement proteins and hence in their immunomodula-
tory capacity and capabilities.
Obviously, the topology of particles is only one source
of properties that may tune the ability to activate com-
plement. By altering the interligand distance from 6 nm
up 14 nm, an almost 1,000-fold increase in the dissoci-
ation constant was observed for the binding of the MBL
oligomers to these surfaces [22]. This disproportional
response, with a two-fold alteration in ligand density caus-
ing a 1,000-fold lowering of the affinity, was interpreted to
reflect the critical difference between binding patterns of
dimensions comparable to the size of MBL and those even
just moderately exceeding these dimensions. As recently
demonstrated by Pacheco et al. [150] for complement
activation through particle surface-bound IgG, there is
a complex interplay between size of the particles and
amount of bound ligand for C1, i.e., the IgG Fc parts,
in regulating the strength of the activation [150]. Similar
to the findings by Pedersen et al. [147], particles with a
diameter of 500 nm appeared more efficient in activating
complement than larger particles with a diameter of
4,000 nm. From careful quantification of the surface-bound
IgG and multiple experiments varying the amount of IgG,
Pacheco et al. hypothesized that an essential trigger of
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via binding to multiple, closely apposed Fc parts [150].
C1 and MBL share several biochemical properties, in
particular with regard to their ultrastructure and ability
of both proteins to form polyvalent interactions. With
this in mind, the critical role of polyvalency for strong
MBL bonding to ligand-presenting surfaces [22], supports
Pacheco et al. hypothesis [150].
As already noted in “Viral infectivity, treatment, and
immunity to influenza” section, complement activation
is an important part of immunity to influenza virus. The
ability of adjuvant to trigger such a response is conse-
quently mimicking conditions that could well be essential
to enable full priming of the adaptive immune system,
which is required to obtain antigen recognition. Im-
portantly, in this scenario, the influence of complement
activation is mediated by the adjuvant particles acting as
“by-standers” creating a milieu of inflammation-stimulating
complement peptides. More specifically, the generation
of the smaller peptide fragments from C3, C4 and C5
may arguably create signatures of the type of complement
activation induced. It may be significant that the adjuvant
mimic the complement activation signature of the natural
infection, which vaccination sought to prevent. For instance,
liposomes appear to trigger a response through the alterna-
tive pathway [151] implying that primarily C3a and C5a
are generated in this process. By contrast, as mentioned
above, influenza virus is most likely activating complement
through all pathways [152] with a prominent role of the
lectin pathway, thereby suggesting the additional presence
of C4a and C2b fragments. Yet, the influences of these
peptidic signatures are only incompletely understood.
As a valuable comparison on how small differences in
proteolytic activities may change the profile of cleavage
products, a recent report demonstrated vast alterations
in the cleavage of soluble protein, and their cutaneous
deposition during inflammation. This emerged as a
consequence of genetic ablation in mice of a single prote-
ase, namely MMP-2 [153]. By analogy, we propose that
regulating the adjuvant-triggered pathway of complement
activation, and hence the proteolytic activities, potentially
could quantitatively and qualitatively improve the out-
come of vaccination.
An even simpler route to immune activation through
the interaction between adjuvant surfaces and body fluid
proteins is derived from the spontaneous surface deposition
of notably albumin and fibrinogen [154]. Such spontaneous
deposition on particle surfaces has been observed to affect
or even destroy the structure of the adsorbed protein in
particle-size-dependent manner [155]. Denatured fibrino-
gen is a ligand for CR3 and CR4 [156]. Hence, the surfaces
of particulate adjuvants play an important role in permit-
ting receptor-mediated contacts between adjuvants and
leukocytes, probably in some cases by manufacturing ahigh density of cues for receptor binding on the particle
surface. Such interactions are extremely strong [34]
and may cause receptor signalling through CR3 leading
to stimulation of cytokine production [157]. Obviously,
the processes discussed above are initiated by simple
contact of the colloidal adjuvant with protein-containing
fluids, notably blood or interstitial fluids, which seems
unavoidable with the chosen routes of vaccine adminis-
tration. As outlined above and also noted from other
studies [158], the transition of soluble proteins onto
surfaces offers a wealth of complex quantitative influences,
which may well manipulate those microenvironments-
developing immune responses. Even so, it is an interesting
observation that both past and present investigations
into the adjuvant properties have largely ignored these
processes and focused on the later cellular responses,
such as modulated receptor expression and activation
of the inflammasome. As noted by Fox et al. [132] this
does not capture the full picture of the processes enabling
the adjuvants to make such stimulations.
It is a classic observation that receptor-mediated endo-
cytosis both have upper and lower limits with regard to
the size range of particulate material that may enter the
cell through a given mechanism [159,160]. Pinocytosis and
receptor-mediated endocytosis brings in to the cytoplasm
relatively small entities such as macromolecules or viral
particles, apparently through a shared use of clathrin
[159]. Receptor-mediated endocytosis is most efficient
with particles taking radii of 25–30 nm with a sharp
cut in efficiency for radii smaller than ~22 nm [160].
These smaller particles may still enter the cells through
pinocytosis albeit less efficiently. By contrast, phagocytosis
enables uptake of particles larger than 500 nm in a process
involving reorganization of the actin cytoskeleton. This
process is typically mediated by Fc receptors, or the
integrins CR3 and CR4 expressed on “professional phago-
cytes” [161], which includes macrophages/dendritic cells,
monocytes, and granulocytes [159,161]. On top of the
size-selectivity in terms of the actual cellular process
mediating the uptake, it is now clear that both micro-
and nanoparticulate material influence these processes
through their shape [162,163]. This influence appears
to derive from the ability of the cell membrane to form
a phagocytic cup covering the particle [164].
In the context of adjuvants, it is of considerable interest
that human B cells are unable to phagocytose particulates
but may endocytose smaller particles [165]. This makes
the large aluminium hydroxide particles unlikely to dir-
ectly enter the cytosol of B cells, while the C3d-tagged
antigens would easily do so. By contrast, the aluminum
hydroxide particles can be phagocytozed by “professional
phagocytes”, which during the intracellular storage may
release the antigen from aluminium hydroxide matrix
and permitting presentation of antigen by myeloid cells
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differences in size of the particulate adjuvant and modi-
fication of molecular adjuvant tags on the antigen could
potentially qualitatively and quantitatively change the
subsets of leukocytes involved in the formation of an
immune response. While the size-difference between
macromolecules and aluminium hydroxide particles are
striking and simple to relate to the known capacity of
certain types of cellular endocytosis, the lipid adjuvants
with sizes intermediate between these extremes are far
more difficult to assign similar discrete mechanisms.
Indeed, based on theoretical calculations and the well-
known ability of macrophages to clear liposomes [142,160],
their size regimen (Table 2) seems to indicate that
both B cells and myeloid cells would be able endo-
cytose or phagocytose these types particulates. At least
on speculative grounds, this would suggest that minor
differences in the size of these adjuvants could tilt
the immune response towards either endocytosis or
phagocytosis-mediated types of uptake hence altering
immunological outcome of vaccination.Conclusions
Vaccination to protect against influenza infection is a
field of great socio-economic and healthcare importance.
The dual targeting of vaccine formulations, engaging both
the innate and adaptive arms of the immune system, is
crucial for efficacy. The TLR recognition of certain ad-
juvants is well documented and may hence serve as the
prototype example for the claim that adjuvants are
essentially enhancers of the innate immune response.
The humoral part of the innate immune system, namely
the complement system, may, however, well be equally
important. In addressing the precise mechanisms of
interactions between the adjuvants and the molecular
environment of the body, we have stressed that in par-
ticular the size of adjuvants may fundamentally regulate
their properties with regard to stimulating the immune
response. The biology of influenza A viruses, notably their
genetic flexibility, is significantly limiting the prospect
of generating a single, omnipotent vaccine formulation.
On the other hand, the conservative choice of adjuvants
seems to ask the question if not more sophisticated strat-
egies would now be of value, here perhaps in particular
benefitting from the available scientific insight on
mechanisms of the innate immune system. We propose
that biophysical properties of the adjuvant formulation,
in particular the dimensions of particulate materials,
offer attractive opportunities to augment the immune
response elicited.
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